Ipamorelin vs SLU-PP-332
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
IpamorelinRecovery & RepairFat Loss & Metabolic
SLU-PP-332- Summary
- Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Half-Life
- 2 hours
- Not established in humans; rodent pharmacokinetics suggest hours
- Admin Route
- SubQ
- Oral (research), Subcutaneous (research)
- Research
- —
- —
- Typical Dose
- 100–300 mcg
- Not established for humans; rodent studies used ~100 mg/kg/day
- Frequency
- Once to twice daily
- Once daily in rodent studies
- Key Benefits
- Increases lean muscle mass
- Enhances fat loss
- Improves recovery time
- Strengthens bones and joints
- Better sleep quality and REM sleep
- Enhanced skin elasticity
- Minimal impact on hunger or cortisol
- No cortisol or prolactin spike
- Clean GH release suitable for long-term protocols
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Side Effects
- Injection site irritation
- Temporary water retention (mild)
- Possible hunger increase (milder than GHRP-6)
- Numbness or tingling in extremities (rare)
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Stacks With
- —
- —